Investigating the Role of Inflammasome in Platelet Activation During Sepsis
Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis
This study is trying to see how a specific part of the immune system affects platelets in people with different levels of sepsis caused by infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 171 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Les Abymes, Guadeloupe) |
| Trial ID | NCT06657781 on ClinicalTrials.gov |
What this trial studies
This observational study aims to estimate and compare the activation rate of the NLRP3 inflammasome in platelets among patients suffering from bacterial and/or viral sepsis, categorized by severity levels using the Sequential Organ Failure Assessment (SOFA) score. It focuses on understanding how platelets contribute to the inflammatory response and cytokine storm associated with sepsis. The study will involve five groups of patients, including those with confirmed bacterial infections and a control group of non-infected patients. By analyzing the levels of pro-inflammatory cytokines and the activation of the inflammasome, the research seeks to clarify the role of platelets in sepsis-related complications.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with confirmed bacterial or viral sepsis.
Not a fit: Patients under 18 years or those who refuse participation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of sepsis mechanisms and lead to improved treatment strategies for patients experiencing severe infections.
How similar studies have performed: While the role of inflammasomes in sepsis is being explored, this specific approach focusing on platelet activation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For all groups: patients older than 18 years at inclusion and acceptation of participation by the patient, his relative or his legal representative (depending on the situation) * For groups 1, 2, 3 and 5: Patient with a confirmed sepsis (microbiological confirmation) * For group 4 : Patient non infected Exclusion Criteria: * Refusal of participation by the patient, his relative or his legal representative (depending on the situation) * Patients subject to a safeguard measure of justice * Patients younger than 18 years at inclusion
Where this trial is running
Les Abymes, Guadeloupe
- Centre Hospitalier Universitaire de la Guadeloup — Les Abymes, Guadeloupe, Guadeloupe (Recruiting)
Study contacts
- Principal investigator: Frédéric MARTINO, Doctor — chu de pointe à pitre
- Study coordinator: Frédéric MARTINO, Doctor
- Email: frederic.martino@chu-guadeloupe.fr
- Phone: +590 590 89 10 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.